Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
Wen Wen, Chen Chen, Jiake Tang, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 516-523
Open Access | Times Cited: 394

Showing 1-25 of 394 citing articles:

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Ronza Najjar‐Debbiny, Naomi Gronich, Regina Weber, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e342-e349
Open Access | Times Cited: 432
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Caroline Stein, Hasan Nassereldine, Reed J D Sorensen, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 833-842
Open Access | Times Cited: 306
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet (2022) Vol. 400, Iss. 10359, pp. 1213-1222
Open Access | Times Cited: 243
Serotonin reduction in post-acute sequelae of viral infection
Andrea C. Wong, Ashwarya S. Devason, Iboro C. Umana, et al.
Cell (2023) Vol. 186, Iss. 22, pp. 4851-4867.e20
Open Access | Times Cited: 208
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
mBio (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 127
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics
Albert Leng, Manuj M. Shah, Syed A. Ahmad, et al.
Cells (2023) Vol. 12, Iss. 5, pp. 816-816
Open Access | Times Cited: 113
Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
Mahrokh Marzi, Mohammad Kazem Vakil, Maryam Bahmanyar, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-16
Open Access | Times Cited: 103
Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches
Jasimuddin Ahamed, Jeffrey Laurence
Journal of Clinical Investigation (2022) Vol. 132, Iss. 15
Open Access | Times Cited: 102
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 87
Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions
Duvuru Geetha, Andreas Kronbichler, Megan Rutter, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 11, pp. 724-737
Open Access | Times Cited: 69
COVID-19 and liver disease
Jean‐François Dufour, Thomas Marjot, Chiara Becchetti, et al.
Gut (2022) Vol. 71, Iss. 11, pp. 2350-2362
Closed Access | Times Cited: 67
Impact of COVID-19 on Cardiovascular Disease
Ivan Vosko, Andreas Zirlik, Heiko Bugger
Viruses (2023) Vol. 15, Iss. 2, pp. 508-508
Open Access | Times Cited: 63
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Mental health status and related factors influencing healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis
Jia Huang, Zhu-Tang Huang, Xin-Ce Sun, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0289454-e0289454
Open Access | Times Cited: 14
The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Chih‐Cheng Lai, Ya‐Hui Wang, Kuang-Hung Chen, et al.
Viruses (2022) Vol. 14, Iss. 8, pp. 1706-1706
Open Access | Times Cited: 59
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2022) Vol. 2022, Iss. 9
Open Access | Times Cited: 53
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitorin vitroand confer resistance to nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 42
COVAD survey 2 long-term outcomes: unmet need and protocol
Zoha Zahid Fazal, Parikshit Sen, Mrudula Joshi, et al.
Rheumatology International (2022) Vol. 42, Iss. 12, pp. 2151-2158
Open Access | Times Cited: 40
Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
Maria Mazzitelli, Daniele Mengato, Lolita Sasset, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 384-384
Open Access | Times Cited: 29
Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches
Valeria Conti, Graziamaria Corbi, Francesco Sabbatino, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 334-334
Open Access | Times Cited: 28
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021–August 2022
Noah Kojima, Katherine Adams, Wesley H. Self, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 4, pp. 547-557
Open Access | Times Cited: 26
Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial
Jianchao Xu, Jinzhong Song, Ziyu Xie, et al.
Medicine (2023) Vol. 102, Iss. 51, pp. e36714-e36714
Open Access | Times Cited: 26
Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
Mykhailo Buchynskyi, Iryna Kamyshna, Katerina Lyubomirskaya, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 25
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 24
Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches
Hafiz Muzzammel Rehman, Muhammad Sajjad, Muhammad Akhtar Ali, et al.
International Journal of Biological Macromolecules (2023) Vol. 237, pp. 124169-124169
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top